SI2269591T1 - Izboljšane farmacevtske formulacije - Google Patents
Izboljšane farmacevtske formulacije Download PDFInfo
- Publication number
- SI2269591T1 SI2269591T1 SI200031095T SI200031095T SI2269591T1 SI 2269591 T1 SI2269591 T1 SI 2269591T1 SI 200031095 T SI200031095 T SI 200031095T SI 200031095 T SI200031095 T SI 200031095T SI 2269591 T1 SI2269591 T1 SI 2269591T1
- Authority
- SI
- Slovenia
- Prior art keywords
- solution
- weight
- fatty acid
- amino
- amount
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract 5
- 150000004668 long chain fatty acids Chemical class 0.000 claims abstract 3
- 239000000203 mixture Substances 0.000 claims abstract 3
- 238000000034 method Methods 0.000 claims 7
- 235000014113 dietary fatty acids Nutrition 0.000 claims 3
- 229930195729 fatty acid Natural products 0.000 claims 3
- 239000000194 fatty acid Substances 0.000 claims 3
- 150000004665 fatty acids Chemical class 0.000 claims 3
- -1 (N -methyl-N - ((2-isopropyl-4-thiazolyl) methyl) amino) carbonyl Chemical group 0.000 claims 2
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims 2
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims 2
- 229960000311 ritonavir Drugs 0.000 claims 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 1
- AMPWQTJNJASABL-UHFFFAOYSA-N 1,6-diphenylhexan-1-amine Chemical compound C=1C=CC=CC=1C(N)CCCCCC1=CC=CC=C1 AMPWQTJNJASABL-UHFFFAOYSA-N 0.000 claims 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 1
- 239000005642 Oleic acid Substances 0.000 claims 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000007904 elastic gelatin capsule Substances 0.000 claims 1
- 239000007903 gelatin capsule Substances 0.000 claims 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 1
- 239000008180 pharmaceutical surfactant Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 108010010369 HIV Protease Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 150000004667 medium chain fatty acids Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrrole Compounds (AREA)
Claims (6)
- Izboljšane farmacevtske formulacije Patentni zahtevki1. Postopek priprave farmacevtskega sestavka, ki vsebuje raztopino, kjer omenjeni postopek obsega polnjenje omenjene raztopine v mehko, elastično želatinasto kapsulo ali v trdno želatinasto kapsulo, kjer omenjena raztopina vsebuje: solubiliziran (2S,3S,5S)-5-(N-(N-((N-metil-N-((2-izopropil-4-tiazolil)metil)amino)karbonil)-L-valinil)-amino)-2-(N-((5-tiazolil)metoksicarbonil)amino)-1,6-difenil-3 -hidroksiheksan (ritonavir), ali kombinacijo solubiliziranega ritonavira in (2S,3S,5S)-2-(2,6-dimetilfenoksiacetil)amino-3-hidroksi-5-(2S-(l-tetrahidropirimid-2-onil)-3-metilbutanoil)amino-l,6-difenilheksana (ABT-378) v količini od 10 do 40 utežnih odstotkov teže omenjene raztopine ali njune farmacevtsko sprejemljive soli; maščobno kislino s srednjo in/ali dolgo verigo ali njune mešanice v količini od 30 do 75 utežnih odstotkov teže omenjene raztopine; farmacevtsko sprejemljiv alkohol; vodo v količini od 0.4 do 3.5 utežnih odstotkov teže omenjene raztopine; in neobvezno, farmacevtsko sprejemljivo površinsko aktivno sredstvo v količini od 0% do 40% teže omenjene raztopine; kjer omenjeni farmacevtsko sprejemljiv alkohol ni etanol v količini od 1 do 15 odstotkov teže omenjene raztopine, kadar je maščobna kislina maščobna kislina z dolgo verigo ali mešanica maščobnih kislin z dolgo verigo.
- 2. Postopek po zahtevku 1, kjer je omenjena maščobna kislina s srednjo in/ali dolgo verigo oleinska kislina.
- 3. Postopek po zahtevku 1, kjer je omenjeno površinsko aktivno sredstvo polioksil 35 ricinusovo olje.
- 4. Postopek po zahtevku 1, kjer raztopina vsebuje od 0.4 do 2.0 utežnih odstotkov vode, glede na skupno težo raztopine.
- 5. Postopek po zahtevku 1, kjer raztopina vsebuje od 0.4 do 1.5 utežnih odstotkov vode, glede na skupno težo raztopine.
- 6. Postopek po zahtevku 1, kjer raztopina vsebuje približno 1 utežni odstotek vode, glede na skupno težo raztopine.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48773900A | 2000-01-19 | 2000-01-19 | |
| EP10177365.3A EP2269591B1 (en) | 2000-01-19 | 2000-12-01 | Improved pharmaceutical formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2269591T1 true SI2269591T1 (sl) | 2018-08-31 |
Family
ID=23936923
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200031095T SI2269591T1 (sl) | 2000-01-19 | 2000-12-01 | Izboljšane farmacevtske formulacije |
| SI200030994T SI1248600T1 (sl) | 2000-01-19 | 2000-12-01 | Izboljšane farmacevtske formulacije inhibitorjev proteaze HIV |
| SI200031073T SI1917958T1 (sl) | 2000-01-19 | 2000-12-01 | Izpopolnjene farmacevtske formulacije inhibitorjev HIV proteaze |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200030994T SI1248600T1 (sl) | 2000-01-19 | 2000-12-01 | Izboljšane farmacevtske formulacije inhibitorjev proteaze HIV |
| SI200031073T SI1917958T1 (sl) | 2000-01-19 | 2000-12-01 | Izpopolnjene farmacevtske formulacije inhibitorjev HIV proteaze |
Country Status (26)
| Country | Link |
|---|---|
| EP (3) | EP1248600B1 (sl) |
| JP (1) | JP4769400B2 (sl) |
| KR (1) | KR100861885B1 (sl) |
| CN (1) | CN100536833C (sl) |
| AT (1) | ATE395049T1 (sl) |
| AU (2) | AU1940501A (sl) |
| BG (1) | BG66112B1 (sl) |
| BR (1) | BR0011864A (sl) |
| CA (1) | CA2395987C (sl) |
| CY (3) | CY1108197T1 (sl) |
| CZ (1) | CZ304118B6 (sl) |
| DE (1) | DE60038899D1 (sl) |
| DK (3) | DK1248600T3 (sl) |
| ES (3) | ES2304990T3 (sl) |
| HK (1) | HK1120213A1 (sl) |
| HU (1) | HU229778B1 (sl) |
| IL (2) | IL150265A0 (sl) |
| MX (1) | MXPA02007097A (sl) |
| NO (1) | NO331400B1 (sl) |
| NZ (1) | NZ519724A (sl) |
| PT (3) | PT1248600E (sl) |
| SI (3) | SI2269591T1 (sl) |
| SK (1) | SK287143B6 (sl) |
| TR (1) | TR201809435T4 (sl) |
| WO (1) | WO2001052821A1 (sl) |
| ZA (1) | ZA200205109B (sl) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE329579T1 (de) | 1999-11-12 | 2006-07-15 | Abbott Lab | Feste dispersion mit ritonavir, fenofibrat oder griseofulvin |
| US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
| GB0615211D0 (en) * | 2006-07-31 | 2006-09-06 | Ge Healthcare Uk Ltd | Asymmetric flouro-substituted polymethine dyes |
| EP2188265A1 (en) * | 2007-08-07 | 2010-05-26 | Ranbaxy Laboratories Limited | Process for preparation of amorphous lopinavir |
| CA2837266A1 (en) | 2011-05-27 | 2012-12-06 | Hetero Research Foundation | Amorphous ritonavir co-precipitated |
| GB201808564D0 (en) * | 2018-05-24 | 2018-07-11 | Douglas Pharmaceuticals Ltd | Treatments |
| GB201808563D0 (en) | 2018-05-24 | 2018-07-11 | Univ Manchester | Treatments |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US594836A (en) * | 1897-11-30 | Corner-brace | ||
| US5354866A (en) | 1989-05-23 | 1994-10-11 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| US5696270A (en) | 1989-05-23 | 1997-12-09 | Abbott Laboratories | Intermediate for making retroviral protease inhibiting compounds |
| GB8927913D0 (en) | 1989-12-11 | 1990-02-14 | Hoffmann La Roche | Amino acid derivatives |
| AU9053191A (en) | 1990-11-19 | 1992-06-11 | Monsanto Company | Retroviral protease inhibitors |
| CA2056911C (en) | 1990-12-11 | 1998-09-22 | Yuuichi Nagano | Hiv protease inhibitors |
| EP0532466A3 (en) | 1991-09-12 | 1993-06-16 | Ciba-Geigy Ag | Derivatives of 5-amino-4-hydroxy-hexanoic acid and their therapeutical use |
| CZ284872B6 (cs) | 1991-10-11 | 1999-03-17 | The Du Pont Merck Pharmaceutical Company | Cyklické močoviny a jejich analogy a farmaceutické přípravky na jejich bázi |
| IL103613A (en) | 1991-11-08 | 1999-05-09 | Merck & Co Inc | VIH protease inhibitors, and the process of preparing intermediates and pharmaceutical preparations containing them. |
| US5413999A (en) | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
| DE69300043T2 (de) | 1992-03-13 | 1995-05-24 | Bio Mega Boehringer Ingelheim | Substituierte Pipecoline-Säurederivate als HIV-Protease-Hemmer. |
| AU676479B2 (en) | 1992-05-20 | 1997-03-13 | G.D. Searle & Co. | Method for making intermediates useful in synthesis of retroviral protease inhibitors |
| US5559256A (en) | 1992-07-20 | 1996-09-24 | E. R. Squibb & Sons, Inc. | Aminediol protease inhibitors |
| IS2334B (is) | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
| US5484926A (en) | 1993-10-07 | 1996-01-16 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
| ATE230402T1 (de) | 1992-12-29 | 2003-01-15 | Abbott Lab | Hemmer der retroviralen protease |
| AU7518694A (en) | 1993-08-20 | 1995-03-21 | G.D. Searle & Co. | Retroviral protease inhibitors and combinations thereof |
| IL110752A (en) | 1993-09-13 | 2000-07-26 | Abbott Lab | Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor |
| US5559158A (en) | 1993-10-01 | 1996-09-24 | Abbott Laboratories | Pharmaceutical composition |
| US5491253A (en) | 1993-10-22 | 1996-02-13 | Abbott Laboratories | Process for the preparation of a substituted 2,5-diamino-3-hydroxyhexane |
| IL111991A (en) | 1994-01-28 | 2000-07-26 | Abbott Lab | Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent |
| IL129871A (en) | 1994-05-06 | 2003-11-23 | Pharmacia & Upjohn Inc | Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections |
| US5567823A (en) | 1995-06-06 | 1996-10-22 | Abbott Laboratories | Process for the preparation of an HIV protease inhibiting compound |
| US6037157A (en) | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
| CA2238977A1 (en) * | 1995-12-13 | 1997-06-19 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| US5914332A (en) | 1995-12-13 | 1999-06-22 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| US6160122A (en) | 1996-06-28 | 2000-12-12 | Abbott Laboratories | Process for the preparation of a disubstituted thiazole |
| ZA9710071B (en) | 1996-11-21 | 1998-05-25 | Abbott Lab | Pharmaceutical composition. |
| KR100815412B1 (ko) * | 1999-06-04 | 2008-03-20 | 아보트 러보러터리즈 | 개선된 약제학적 제형 |
-
2000
- 2000-12-01 PT PT00982360T patent/PT1248600E/pt unknown
- 2000-12-01 AU AU19405/01A patent/AU1940501A/en not_active Abandoned
- 2000-12-01 TR TR2018/09435T patent/TR201809435T4/tr unknown
- 2000-12-01 SI SI200031095T patent/SI2269591T1/sl unknown
- 2000-12-01 PT PT101773653T patent/PT2269591T/pt unknown
- 2000-12-01 ES ES00982360T patent/ES2304990T3/es not_active Expired - Lifetime
- 2000-12-01 EP EP00982360A patent/EP1248600B1/en not_active Revoked
- 2000-12-01 HU HU0302070A patent/HU229778B1/hu not_active IP Right Cessation
- 2000-12-01 PT PT07121429T patent/PT1917958E/pt unknown
- 2000-12-01 SI SI200030994T patent/SI1248600T1/sl unknown
- 2000-12-01 NZ NZ519724A patent/NZ519724A/en not_active IP Right Cessation
- 2000-12-01 SK SK1110-2002A patent/SK287143B6/sk not_active IP Right Cessation
- 2000-12-01 DK DK00982360T patent/DK1248600T3/da active
- 2000-12-01 WO PCT/US2000/032771 patent/WO2001052821A1/en active IP Right Grant
- 2000-12-01 EP EP07121429A patent/EP1917958B1/en not_active Revoked
- 2000-12-01 SI SI200031073T patent/SI1917958T1/sl unknown
- 2000-12-01 BR BR0011864-8A patent/BR0011864A/pt not_active Application Discontinuation
- 2000-12-01 IL IL15026500A patent/IL150265A0/xx unknown
- 2000-12-01 DK DK10177365.3T patent/DK2269591T3/en active
- 2000-12-01 MX MXPA02007097A patent/MXPA02007097A/es active IP Right Grant
- 2000-12-01 EP EP10177365.3A patent/EP2269591B1/en not_active Revoked
- 2000-12-01 ES ES10177365.3T patent/ES2676151T3/es not_active Expired - Lifetime
- 2000-12-01 DE DE60038899T patent/DE60038899D1/de not_active Expired - Lifetime
- 2000-12-01 KR KR1020027009316A patent/KR100861885B1/ko active IP Right Grant
- 2000-12-01 ES ES07121429T patent/ES2387579T3/es not_active Expired - Lifetime
- 2000-12-01 CZ CZ20022663A patent/CZ304118B6/cs not_active IP Right Cessation
- 2000-12-01 JP JP2001552869A patent/JP4769400B2/ja not_active Expired - Lifetime
- 2000-12-01 CN CNB008184798A patent/CN100536833C/zh not_active Expired - Lifetime
- 2000-12-01 DK DK07121429.0T patent/DK1917958T3/da active
- 2000-12-01 AT AT00982360T patent/ATE395049T1/de active
- 2000-12-01 CA CA002395987A patent/CA2395987C/en not_active Expired - Lifetime
-
2002
- 2002-06-17 IL IL150265A patent/IL150265A/en active IP Right Grant
- 2002-06-25 ZA ZA200205109A patent/ZA200205109B/xx unknown
- 2002-07-18 NO NO20023455A patent/NO331400B1/no not_active Application Discontinuation
- 2002-08-02 BG BG106976A patent/BG66112B1/bg unknown
-
2006
- 2006-11-07 AU AU2006235895A patent/AU2006235895B2/en not_active Revoked
-
2008
- 2008-07-16 CY CY20081100740T patent/CY1108197T1/el unknown
- 2008-11-04 HK HK08112065.7A patent/HK1120213A1/xx not_active IP Right Cessation
-
2012
- 2012-08-07 CY CY20121100711T patent/CY1112995T1/el unknown
-
2018
- 2018-07-03 CY CY20181100697T patent/CY1120408T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170325T1 (hr) | Farmaceutska doza koja sadrži farmaceutski prihvatljivu otapajuću smjesu | |
| AR055734A1 (es) | Una formulacion solida de dosificacion farmaceutica | |
| CL2008003491A1 (es) | Composicion farmaceutica en solucion que comprende ritonavir, un solvente organico que comprende un acido graso de cadena larga entre un 30-75% en peso total, agua entre 0,4-3,5% en peso total y opcionalmente un surfactante (divisional de la solicitud 1257-00). | |
| HRP20010343B1 (en) | Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent | |
| KR960703589A (ko) | 사람 면역결핍 바이러스-프로테아제 억제제의 약제학적 조성물(Pharmaceutical composition of HIV-protease inhibitors) | |
| KR100478075B1 (ko) | 리토나비르 및 c12 - c18 지방산을 포함하는 경구 투여용 약제학적 조성물 | |
| CA2359945A1 (en) | Inhibitors of crystallization in a solid dispersion | |
| KR960703567A (ko) | 약제학적 조성물(Pharmaceutical composition) | |
| KR100824547B1 (ko) | 사이토크롬p450에의해대사되는약물의약력학을개선하기위한리토나비르(abt-538)의용도 | |
| JP2003501386A5 (sl) | ||
| AR049658A2 (es) | Ritonavir amorfo, su uso en la fabricacion de un medicamento, composicion farmaceutica, proceso para su preparacion y proceso para la preparacion de la forma polimorfa cristalina i de ritonavir. | |
| DE69620882D1 (de) | Verfahren zur herstellung eines hiv-protease inhibitor | |
| SI2269591T1 (sl) | Izboljšane farmacevtske formulacije | |
| PE20001296A1 (es) | El uso de una combinacion de tipranavir y ritonavir para mejorar la farmacocinetica del tipranavir | |
| JP2003533435A5 (sl) | ||
| PT1446404E (pt) | Edisilatos de rosiglitazona e sua utilizacao como antidiabeticos | |
| PE20030098A1 (es) | Capsulas elasticas blandas y composiciones de las mismas | |
| AU757970B2 (en) | Pharmaceutical composition | |
| WO2003105826B1 (en) | STABLE AND SOLUBLE PHARMACEUTICAL COMPOSITION FOR THE DELIVERY OF HIV PROTEASE INHIBITORS AND METHOD FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS FOR THE DELIVERY OF HIV PROTEASE INHIBITORS | |
| RU2021136579A (ru) | Новые гепатопротекторные средства | |
| EA200300423A1 (ru) | Производное тиазолидиндиона и его применение в качестве противодиабетического лекарственного средства |